参考文献/References:
[1] Roth GA,Johnson C,Abajobir A,et al. Global,regional and national burden of cardiovascular diseases for 10 causes,1990 to 2015[J]. J Am Coll Cardiol,2017,70(1):1-25.
[2] Inagaki?N,Harashima?SI,Iijima?H,et al. Canagliflozin for the treatment of type 2 diabetes:a comparison between Japanese and non-Japanese patients[J].ExpertOpin Pharmacother, 2018, 19(8):895-908.
[3] Zinman B,Wanner C,Lachin JM,et al. Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes [J]. N Engl J Med,2015,373(22):2117-2128.
[4] Neal B,Perkovic V,Mahaffey KW,et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes [J]. N Engl J Med,2017,377(7):644-657.
[5] Himokawa H,Miura M,Nochioka K,et al. Heart failure as a general pandemic in Asia [J]. Eur J Heart Fail,2015,17(9):884-892.
[6] Heerspink HJ,Perkins BA,Fitchett DH,et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus:cardiovascular and kidney effects,potential mechanisms and clinical applications [J]. Circulation,2016,134(10):752-772.
[7] American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes-2019.[J]. Diabetes Care,2019,42(Suppl 1):S103-S123.
[8] Vigay V,Singh KP. Use of dapagliflozin in the management of type 2 diabetes mellitus:a real-world evidence study in Indian patients(FOREFRONT)[J]. Diabetes Technol Ther,2019,21(8):415-422.
[9] Cho YK,Lee J,Kang YM,et al. Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes[J]. PLoS One,2019,14(8):e0220667.
[10] Ishihara H,Yamaguchi S,Nakao I,etal.Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE):A 52-Week Open-Label Study[J]. Diabetes Ther,2018,9(4):1549-1567.
[11] Kawamori R,Haneda M,Suzaki K. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes:Glycaemic efficacy and safety profile in a 52-week,randomized,placebo-controlled trial[J]. Diabetes Obes Metab,2018,20(9):2200-2209.
[12] Ji L,Han P,Liu Y,et al. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea [J]. Diabetes Obes Metab,2015,17(1):23-31.
[13] Seino Y,Sasaki T,Fukatsu A,et al. Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes:a multicenter,52-week,clinical study with a 16-week,double-blind period and a 36-week,open-label period[J]. Curr Med Res Opin,2018,34(6):981-994.
[14] Yang W,Ma J,Li Y,et al. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs:a randomized controlled trial [J]. J Diabetes,2018,10(7):589-599.
[15] Feng M,Lv H,Xu X,et al . Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus:a meta-analysis of randomized controlled trials[J]. Medicine (Baltimore), 2019,98(30):e16575.
[16] Lim LL,Tan AT,Moses K,et al. Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus:insights into the management of Asian phenotype [J].J Diabetes Complications,2017,31(2):494-503.
[17] Filippas-Ntekouan S,Tsimihodimos V,Filippatos T,et al. SGLT-2 inhibitors:pharmacokinetics characteristics and effects on lipids[J]. Expert Opin Drug Metab Toxicol,2018,14(11):1113-1121.
[18] Kim?MK,Ko?SH,Kim?BY,et al. 2019 Clinical practice guidelines for type 2 diabetes mellitus in Korea[J]. Diabetes Metab J,2019,43(4):398-406.
[19] Inzucchi SE,Zinman B,Fitchett D,et al. How does empagliflozin reduce cardiovascular mortality?insights from a mediation analysis of the EMPA-REG OUTCOME trial[J]. Diabetes Care,2018,41(2):356-363.
[20] Vallon V,Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia:the pleiotropic effects of SGLT2 inhibition[J]. Diabetologia,2017,60(2):215-225.
[21] Bekki M,Tahara N,Tahara A,et al. Switching dipeptidyl peptidase-4 inhibitors to tofogliflozin,a selective inhibitor of sodium-glucose cotransporter 2 improve arterial stiffness evaluated by cardio-ankle vascular index in patients with type 2 diabetes:a pilot study[J]. Curr Vasc Pharmacol,2019,17(4):411-420.
[22] Lunder M,Jani? M,Japelj M,et al. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus[J]. Cardiovasc Diabetol,2018,17(1):153.
[23] Adingupu DD,G?pel SO,Gr?nros J,et al. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob-/- mice[J]. Cardiovasc Diabetol,2019,18(1):16.
[24] Kaku K,Lee J,Mattheus M,et al. Empaglifozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease—results from EMPA-REG OUTCOME?[J]. Circ J,2017,81(2):227-234.
[25] Sano M,Takei M,Shiraishi Y,et al. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys[J]. J Clin Med Res,2016,8(12):844-847.
[26] Hayashi T,Fukui T,Nakanishi N,et al. Dapagliflozin decreases small dense low-density lipoprotein cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes:comparison with sitagliptin [J]. Cardiovasc Diabetol,2017,16(1):149.
[27] Mudaliar S,Polidori D,Zambrowicz B,et al. Sodium-glucose cotransporter inhibitors:effects on renal and intestinal glucose transport:from bench to bedside[J]. Diabetes Care ,2015,38(12):2344-2353.
[28] Wiviott SD,Raz I,Bonaca MP,et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2019,380(4):347-357.
[29] Zelniker TA,Wiviott SD,Raz I,et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes:a systematic review and meta-analysis of cardiovascular outcome trials [J]. Lancet,2019,393(10166):31-39.
[30] Cai X,Gao X,Yang W,et al. No disparity of the efficacy and all cause mortality between Asian and non-Asian type 2 diabetes patients with SGLT2 inhibitors treatment:a meta-analysis[J]. J Diabetes Investig,2018,9(4):850-861
[31] Kosiborod M,Lam CSP,Kohsaka S,et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs:The CVD-REAL 2 study[J]. J Am Coll Cardiol,2018,71(23):2628-2639.
[32] Packer M. Reconceptualization of the molecular mechanism by which sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure events[J]. Circulation,2019,140(6):443-445.
[33] Bonora BM,Vigili de Kreutzenberg S,Avogaro A,et al. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial[J]. Cardiovasc Diabetol,2019,18(1):106.
[34] Garvey WT,van GL,Leiter LA,et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes[J]. Metabolism,2018,85:32-37.
[35] Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors[J]. Diabetes Obes Metab,2019,21(6):1291-1298.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(3):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(3):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(3):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(3):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(3):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
[11]耿肖囡 肖东斌 魏鑫 惠学志.达格列净对心血管疾病的预防保护机制[J].心血管病学进展,2019,(8):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
GENG Xiaonan,XIAO Dongbin,WEI xin,et al.Preventive and Protective Mechanism of Dagliflozin for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
[12]张欣 郭艺芳.钠-葡萄糖协同转运蛋白2抑制剂相关心血管益处的可能潜在机制[J].心血管病学进展,2020,(9):903.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.004]
ZHANG Xin,GUO Yifang.Potential Mechanisms of Sodium-glucose Co-transporter 2 Inhibitor-related Cardiovascular Benefits[J].Advances in Cardiovascular Diseases,2020,(3):903.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.004]